Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul;42(7):585-589.
doi: 10.1002/phar.2706. Epub 2022 Jun 8.

Myocardial infarction associated with erenumab: A case report

Justine Perino  1   2 , Virginie Corand  3 , Elise Laurent  1 , Hélène Théophile  1 , Ghada Miremont-Salamé  1 , Antoine Pariente  1   2 , Jean-Laurent Colas  4 , Thierry Couffinhal  5 , Francesco Salvo  1   2
Affiliations
Case Reports

Myocardial infarction associated with erenumab: A case report

Justine Perino et al. Pharmacotherapy. 2022 Jul.

Abstract

Background: Monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab.

Case: A 57-year-old woman with a familial history of coronaropathy was first treated with erenumab 70 mg for 6 months and then increased to 140 mg. Almost 5 months after, the patient presented chest pain, increased troponin, and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI.

Conclusion: Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate examinations to measure the burden of coronary atherosclerosis, if necessary.

Keywords: adverse event; calcitonin gene-related peptide; case report; drug safety; migraine disorder; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

Virginie Corand has declared conflict of interest with Lilly, Teva, and Novartis. The other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

FIGURE 1
FIGURE 1
Electrocardiogram recorded at hospitalization admission
FIGURE 2
FIGURE 2
Cardiac magnetic resonance imaging showing non‐transmural subendocardial perfusion defect in the medial inferior territory
See this image and copyright information in PMC

References

    1. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target ‐in the treatment of headache. Cephalalgia. 2004;24:611‐622. - PubMed
    1. Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5‐HT1D‐receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia. 2002;22:424‐431. - PubMed
    1. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin Gene‐Related Peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099‐1142. - PMC - PubMed
    1. Kee Z, Kodji X, Brain SD. The role of Calcitonin Gene Related Peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects. Front Physiol. 2018;9:1249. - PMC - PubMed
    1. Rivera‐Mancilla E, Villalón CM, MaassenVanDenBrink A. CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opin Drug Saf. 2020;19:1237‐1250. - PubMed

Publication types

MeSH terms

Substances